Alfred S Lewin

List of Publications by Year
in descending order

176	8,715	57758	58581
papers	citations	44 h-index	82 g-index

179	179	179	8100
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Gene Delivery of a Caspase Activation and Recruitment Domain Improves Retinal Pigment Epithelial Function and Modulates Inflammation in a Mouse Model with Features of Dry Age-Related Macular Degeneration. Journal of Ocular Pharmacology and Therapeutics, 2022, 38, 359-371.	1.4	3
2	Automated segmentation and analysis of retinal microglia within ImageJ. Experimental Eye Research, 2021, 203, 108416.	2.6	6
3	Corneal Application of R9-SOCS1-KIR Peptide Alleviates Endotoxin-Induced Uveitis. Translational Vision Science and Technology, 2021, 10, 25.	2.2	7
4	Erythropoietin Gene Therapy Delays Retinal Degeneration Resulting from Oxidative Stress in the Retinal Pigment Epithelium. Antioxidants, 2021, 10, 842.	5.1	8
5	Gene Therapy for Rhodopsin-associated Autosomal Dominant Retinitis Pigmentosa. International Ophthalmology Clinics, 2021, 61, 79-96.	0.7	7
6	Sectoral activation of glia in an inducible mouse model of autosomal dominant retinitis pigmentosa. Scientific Reports, 2020, 10, 16967.	3.3	10
7	SOCS, Intrinsic Virulence Factors, and Treatment of COVID-19. Frontiers in Immunology, 2020, 11, 582102.	4.8	31
8	A C-terminal peptide from type I interferon protects the retina in a mouse model of autoimmune uveitis. PLoS ONE, 2020, 15, e0227524.	2.5	5
9	Title is missing!. , 2020, 15, e0227524.		0
10	Title is missing!. , 2020, 15, e0227524.		0
11	Title is missing!. , 2020, 15, e0227524.		0
12	Title is missing!. , 2020, 15, e0227524.		0
13	Expression of a CARD Slows the Retinal Degeneration of a Geographic Atrophy Mouse Model. Molecular Therapy - Methods and Clinical Development, 2019, 14, 113-125.	4.1	9
14	Biodistribution of adeno-associated virus type 2 with mutations in the capsid that contribute to heparan sulfate proteoglycan binding. Virus Research, 2019, 274, 197771.	2.2	10
15	Meet Our Co-Editor. Current Gene Therapy, 2019, 19, 139-139.	2.0	0
16	Mitochondrial oxidative stress in the retinal pigment epithelium (RPE) led to metabolic dysfunction in both the RPE and retinal photoreceptors. Redox Biology, 2019, 24, 101201.	9.0	146
17	Myxoma virus M013 protein antagonizes NF-Î²B and inflammasome pathways via distinct structural motifs. Journal of Biological Chemistry, 2019, 294, 8480-8489.	3.4	9
18	Co-Delivery of a Short-Hairpin RNA and a shRNA-Resistant Replacement Gene with Adeno-Associated Virus: An Allele-Independent Strategy for Autosomal-Dominant Retinal Disorders. Methods in Molecular Biology, 2019, 1937, 235-258.	0.9	5

#	Article	IF	Citations
19	AAV Mediated Delivery of Myxoma Virus M013 Gene Protects the Retina against Autoimmune Uveitis. Journal of Clinical Medicine, 2019, 8, 2082.	2.4	5
20	SRD005825 Acts as a Pharmacologic Chaperone of Opsin and Promotes Survival of Photoreceptors in an Animal Model of Autosomal Dominant Retinitis Pigmentosa. Translational Vision Science and Technology, 2019, 8, 30.	2.2	6
21	AMPK May Play an Important Role in theÂRetinal Metabolic Ecosystem. Advances in Experimental Medicine and Biology, 2019, 1185, 477-481.	1.6	5
22	Mitochondria: Potential Targets for Protection in Age-Related Macular Degeneration. Advances in Experimental Medicine and Biology, 2018, 1074, 11-17.	1.6	46
23	Neuroinflammation in Retinitis Pigmentosa, Diabetic Retinopathy, and Age-Related Macular Degeneration: A Minireview. Advances in Experimental Medicine and Biology, 2018, 1074, 185-191.	1.6	29
24	Delivery of CR2-fH Using AAV Vector Therapy as Treatment Strategy in the Mouse Model of Choroidal Neovascularization. Molecular Therapy - Methods and Clinical Development, 2018, 9, 1-11.	4.1	29
25	Clinically Relevant Outcome Measures for the I307N Rhodopsin Mouse: A Model of Inducible Autosomal Dominant Retinitis Pigmentosa. , 2018, 59, 5417.		13
26	Daily zeaxanthin supplementation prevents atrophy of the retinal pigment epithelium (RPE) in a mouse model of mitochondrial oxidative stress. PLoS ONE, 2018, 13, e0203816.	2.5	43
27	Adeno-Associated Virus Delivery of Viral Serpins for Ocular Diseases: Design and Validation. Methods in Molecular Biology, 2018, 1826, 237-254.	0.9	1
28	Preface: Translational Gene Therapy Coming of Age!. Current Gene Therapy, 2018, 18, 1-1.	2.0	1
29	A cell penetrating peptide from SOCS-1 prevents ocular damage in experimental autoimmune uveitis. Experimental Eye Research, 2018, 177, 12-22.	2.6	29
30	Cell-specific gene therapy driven by an optimized hypoxia-regulated vector reduces choroidal neovascularization. Journal of Molecular Medicine, 2018, 96, 1107-1118.	3.9	13
31	Mutation-independent rhodopsin gene therapy by knockdown and replacement with a single AAV vector. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E8547-E8556.	7.1	114
32	In Vivo Knockdown of the Herpes Simplex Virus 1 Latency-Associated Transcript Reduces Reactivation from Latency. Journal of Virology, 2018, 92, .	3.4	41
33	Systemic Injection of RPE65-Programmed Bone Marrow-Derived Cells Prevents Progression of Chronic Retinal Degeneration. Molecular Therapy, 2017, 25, 917-927.	8.2	19
34	Oxidative stress-mediated NFÎºB phosphorylation upregulates p62/SQSTM1 and promotes retinal pigmented epithelial cell survival through increased autophagy. PLoS ONE, 2017, 12, e0171940.	2.5	78
35	Timing of Antioxidant Gene Therapy: Implications for Treating Dry AMD. , 2017, 58, 1237.		24
36	Meet Our Co-Editor. Current Gene Therapy, 2017, 17, .	2.0	0

#	Article	IF	Citations
37	Targeting the Nrf2 Signaling Pathway in the Retina With a Gene-Delivered Secretable and Cell-Penetrating Peptide. , 2016, 57, 372.		30
38	MRI of Retinal Free Radical Production With Laminar Resolution In Vivo. , 2016, 57, 577.		31
39	Adeno-associated Virus Vectors Efficiently Transduce Mouse and Rabbit Sensory Neurons Coinfected with Herpes Simplex Virus 1 following Peripheral Inoculation. Journal of Virology, 2016, 90, 7894-7901.	3.4	16
40	Conditional Induction of Oxidative Stress in RPE: A Mouse Model of Progressive Retinal Degeneration. Advances in Experimental Medicine and Biology, 2016, 854, 31-37.	1.6	18
41	The NLRP3 Inflammasome and its Role in Age-Related Macular Degeneration. Advances in Experimental Medicine and Biology, 2016, 854, 59-65.	1.6	26
42	Ablation of Chop Transiently Enhances Photoreceptor Survival but Does Not Prevent Retinal Degeneration in Transgenic Mice Expressing Human P23H Rhodopsin. Advances in Experimental Medicine and Biology, 2016, 854, 185-191.	1.6	24
43	Characterization of Ribozymes Targeting a Congenital Night Blindness Mutation in Rhodopsin Mutation. Advances in Experimental Medicine and Biology, 2016, 854, 509-515.	1.6	1
44	Erythropoietin Slows Photoreceptor Cell Death in a Mouse Model of Autosomal Dominant Retinitis Pigmentosa. PLoS ONE, 2016, 11, e0157411.	2.5	7
45	Repurposing an orally available drug for the treatment of geographic atrophy. Molecular Vision, 2016, 22, 294-310.	1.1	9
46	Gene Delivery of a Viral Anti-Inflammatory Protein to Combat Ocular Inflammation. Human Gene Therapy, 2015, 26, 59-68.	2.7	28
47	Gene Therapy With the Caspase Activation and Recruitment Domain Reduces the Ocular Inflammatory Response. Molecular Therapy, 2015, 23, 875-884.	8.2	22
48	Endurance training ameliorates complex 3 deficiency in a mouse model of Barth syndrome. Journal of Inherited Metabolic Disease, 2015, 38, 915-922.	3.6	14
49	Consequences of zygote injection and germline transfer of mutant human mitochondrial DNA in mice. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E5689-98.	7.1	31
50	Successful arrest of photoreceptor and vision loss expands the therapeutic window of retinal gene therapy to later stages of disease. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E5844-53.	7.1	75
51	Systemic treatment with a 5HT1a agonist induces anti-oxidant protection and preserves the retina from mitochondrial oxidative stress. Experimental Eye Research, 2015, 140, 94-105.	2.6	31
52	Gene Augmentation for X-Linked Retinitis Pigmentosa Caused by Mutations in RPGR. Cold Spring Harbor Perspectives in Medicine, 2015, 5, a017392-a017392.	6.2	19
53	Gene Therapy to Rescue Retinal Degeneration Caused by Mutations in Rhodopsin. Methods in Molecular Biology, 2015, 1271, 391-410.	0.9	8
54	Dysregulated autophagy in the RPE is associated with increased susceptibility to oxidative stress and AMD. Autophagy, 2014, 10, 1989-2005.	9.1	352

#	Article	IF	Citations
55	Gene Augmentation for adRP Mutations in RHO. Cold Spring Harbor Perspectives in Medicine, 2014, 4, a017400-a017400.	6.2	33
56	Safety and Effects of the Vector for the Leber Hereditary Optic Neuropathy Gene Therapy Clinical Trial. JAMA Ophthalmology, 2014, 132, 409.	2.5	83
57	Drug and Gene Delivery to the Back of the Eye: From Bench to Bedside. , 2014, 55, 2714.		97
58	LHON Gene Therapy Vector Prevents Visual Loss and Optic Neuropathy Induced by G11778A Mutant Mitochondrial DNA: Biodistribution and Toxicology Profile. Investigative Ophthalmology and Visual Science, 2014, 55, 7739-7753.	3.3	52
59	Assessment of anti-scarring therapies in exÂvivo organ cultured rabbit corneas. Experimental Eye Research, 2014, 125, 173-182.	2.6	30
60	Mitochondrial Oxidative Stress in the Retinal Pigment Epithelium Leads to Localized Retinal Degeneration. , 2014, 55, 4613.		89
61	Modulation of the Rate of Retinal Degeneration in T17M RHO Mice by Reprogramming the Unfolded Protein Response.. Advances in Experimental Medicine and Biology, 2014, 801, 455-462.	1.6	9
62	Triple Combination of siRNAs Targeting TGFÎ²1, TGFÎ²R2, and CTGF Enhances Reduction of Collagen I and Smooth Muscle Actin in Corneal Fibroblasts. , 2013, 54, 8214.		32
63	A Comprehensive Review of Retinal Gene Therapy. Molecular Therapy, 2013, 21, 509-519.	8.2	245
64	In Vitro and in Vivo Characterization of a Tunable Dual-Reactivity Probe of the Nrf2-ARE Pathway. ACS Chemical Biology, 2013, 8, 1764-1774.	3.4	18
65	NADH-dehydrogenase Type-2 Suppresses Irreversible Visual Loss and Neurodegeneration in the EAE Animal Model of MS. Molecular Therapy, 2013, 21, 1876-1888.	8.2	28
66	Ablation of C/EBP Homologous Protein Does Not Protect T17M RHO Mice from Retinal Degeneration. PLoS ONE, 2013, 8, e63205.	2.5	32
67	Reduction of corneal scarring in rabbits by targeting the TGFB1 pathway with a triple siRNA combination. Advances in Bioscience and Biotechnology (Print), 2013, 04, 47-55.	0.7	11
68	Glucose Regulated Protein 78 Diminishes Î±-Synuclein Neurotoxicity in a Rat Model of Parkinson Disease. Molecular Therapy, 2012, 20, 1327-1337.	8.2	154
69	ACE2 and Ang-(1-7) Confer Protection Against Development of Diabetic Retinopathy. Molecular Therapy, 2012, 20, 28-36.	8.2	143
70	Gene delivery to mitochondria by targeting modified adenoassociated virus suppresses Leberâ€™s hereditary optic neuropathy in a mouse model. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, E1238-47.	7.1	153
71	Gene therapy rescues photoreceptor blindness in dogs and paves the way for treating human X-linked retinitis pigmentosa. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 2132-2137.	7.1	237
72	Long-Term Rescue of Retinal Structure and Function by Rhodopsin RNA Replacement with a Single Adeno-Associated Viral Vector in P23HRHOTransgenic Mice. Human Gene Therapy, 2012, 23, 356-366.	2.7	76

#	Article	IF	Citations
73	Pathological consequences of long-term mitochondrial oxidative stress in the mouse retinal pigment epithelium. Experimental Eye Research, 2012, 101, 60-71.	2.6	44
74	Hammerhead Ribozyme-Mediated Knockdown of mRNA for Fibrotic Growth Factors: Transforming Growth Factor-Beta 1 and Connective Tissue Growth Factor. Methods in Molecular Biology, 2012, 820, 117-132.	0.9	6
75	The 5HT1a Receptor Agonist 8-Oh DPAT Induces Protection from Lipofuscin Accumulation and Oxidative Stress in the Retinal Pigment Epithelium. PLoS ONE, 2012, 7, e34468.	2.5	35
76	Proteolytic Processing of Connective Tissue Growth Factor in Normal Ocular Tissues and during Corneal Wound Healing. , 2012, 53, 8093.		16
77	Functional Rescue of P23H Rhodopsin Photoreceptors by Gene Delivery. Advances in Experimental Medicine and Biology, 2012, 723, 191-197.	1.6	21
78	Gene Delivery of Wild-Type Rhodopsin Rescues Retinal Function in an Autosomal Dominant Retinitis Pigmentosa Mouse Model. Advances in Experimental Medicine and Biology, 2012, 723, 199-205.	1.6	7
79	Suppression of rds Expression by siRNA and Gene Replacement Strategies for Gene Therapy Using rAAV Vector. Advances in Experimental Medicine and Biology, 2012, 723, 215-223.	1.6	22
80	NADPH Oxidase in Choroidal Neovascularization. , 2012, , 307-320.		0
81	The Role of Mitochondrial Oxidative Stress in Retinal Dysfunction. , 2012, , 203-239.		1
82	Mutant NADH dehydrogenase subunit 4 gene delivery to mitochondria by targeting sequence-modified adeno-associated virus induces visual loss and optic atrophy in mice. Molecular Vision, 2012, 18, 1668-83.	1.1	30
83	Gene therapy in animal models of autosomal dominant retinitis pigmentosa. Molecular Vision, 2012, 18, 2479-96.	1.1	47
84	Novel Properties of Tyrosine-mutant AAV2 Vectors in the Mouse Retina. Molecular Therapy, 2011, 19, 293-301.	8.2	234
85	AAV Delivery of Wild-Type Rhodopsin Preserves Retinal Function in a Mouse Model of Autosomal Dominant Retinitis Pigmentosa. Human Gene Therapy, 2011, 22, 567-575.	2.7	104
86	Characterization of a Transgenic Short Hairpin RNA-Induced Murine Model of Tafazzin Deficiency. Human Gene Therapy, 2011, 22, 865-871.	2.7	114
87	rAAV2/5 gene-targeting to rods:dose-dependent efficiency and complications associated with different promoters. Gene Therapy, 2010, 17, 1162-1174.	4.5	70
88	Restoration of visual function in P23H rhodopsin transgenic rats by gene delivery of BiP/Grp78. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 5961-5966.	7.1	265
89	In Vivo RNAi-Mediated Î±-Synuclein Silencing Induces Nigrostriatal Degeneration. Molecular Therapy, 2010, 18, 1450-1457.	8.2	173
90	The Importance of Mitochondria in Age-Related and Inherited Eye Disorders. Ophthalmic Research, 2010, 44, 179-190.	1.9	91

#	Article	IF	Citations
91	Regulatory RNA in Gene Therapy. , 2010, , 103-122.		1
92	Delivery of Antioxidant Enzyme Genes to Protect against Ischemia/Reperfusion-Induced Injury to Retinal Microvasculature. , 2009, 50, 5587.		34
93	Efficiency and Safety of AAV-Mediated Gene Delivery of the Human ND4 Complex I Subunit in the Mouse Visual System. , 2009, 50, 4205.		76
94	Geographic Atrophy in Age-Related Macular Degeneration andTLR3. New England Journal of Medicine, 2009, 360, 2251-2256.	27.0	9
95	Tight Long-term Dynamic Doxycycline Responsive Nigrostriatal GDNF Using a Single rAAV Vector. Molecular Therapy, 2009, 17, 1857-1867.	8.2	63
96	High-efficiency Transduction of the Mouse Retina by Tyrosine-mutant AAV Serotype Vectors. Molecular Therapy, 2009, 17, 463-471.	8.2	355
97	AAVâ€mediated knockdown of phospholamban leads to improved contractility and calcium handling in cardiomyocytes. Journal of Gene Medicine, 2008, 10, 132-142.	2.8	29
98	Unexpected off-targeting effects of anti-huntingtin ribozymes and siRNA in vivo. Neurobiology of Disease, 2008, 29, 446-455.	4.4	21
99	Gene Therapy for Mouse Models of ADRP. Advances in Experimental Medicine and Biology, 2008, 613, 107-112.	1.6	5
100	Reduction in Severity of a Herpes Simplex Virus Type 1 Murine Infection by Treatment with a Ribozyme Targeting the U L 20 Gene RNA. Journal of Virology, 2008, 82, 7467-7474.	3.4	15
101	Downregulation of p22phox in Retinal Pigment Epithelial Cells Inhibits Choroidal Neovascularization in Mice. Molecular Therapy, 2008, 16, 1688-1694.	8.2	38
102	Range of Retinal Diseases Potentially Treatable by AAV-Vectored Gene Therapy. Novartis Foundation Symposium, 2008, , 179-194.	1.1	18
103	In vitro Analysis of Ribozyme-mediated Knockdown of an ADRP Associated Rhodopsin Mutation. Advances in Experimental Medicine and Biology, 2008, 613, 97-106.	1.6	4
104	Use of Mitochondrial Antioxidant Defenses for Rescue of Cells With a Leber Hereditary Optic Neuropathyâ€“Causing Mutation. JAMA Ophthalmology, 2007, 125, 268.	2.4	51
105	Long-term Suppression of Neurodegeneration in Chronic Experimental Optic Neuritis: Antioxidant Gene Therapy. , 2007, 48, 5360.		52
106	SOD2 Knockdown Mouse Model of Early AMD. , 2007, 48, 4407.		201
107	Preservation of photoreceptor morphology and function in P23H rats using an allele independent ribozyme. Experimental Eye Research, 2007, 84, 44-52.	2.6	85
108	rAAV-mediated nigral human parkin over-expression partially ameliorates motor deficits via enhanced dopamine neurotransmission in a rat model of Parkinson's disease. Experimental Neurology, 2007, 207, 289-301.	4.1	62

#	Article	IF	Citations
109	Down-regulation of expression of rat pyruvate dehydrogenase E1Î± gene by self-complementary adeno-associated virus-mediated small interfering RNA delivery. Mitochondrion, 2007, 7, 253-259.	3.4	11
110	Anti-clarin-1 AAV-delivered ribozyme induced apoptosis in the mouse cochlea. Hearing Research, 2007, 230, 9-16.	2.0	14
111	Suppression of Mitochondrial Oxidative Stress Provides Long-term Neuroprotection in Experimental Optic Neuritis. , 2007, 48, 681.		115
112	The Mutant Human ND4 Subunit of Complex I Induces Optic Neuropathy in the Mouse. , 2007, 48, 1.		107
113	Increased Sensitivity to Light-Induced Damage in a Mouse Model of Autosomal Dominant Retinal Disease. , 2007, 48, 1942.		58
114	Rapid, widespread transduction of the murine myocardium using self-complementary Adeno-associated virus. Genetic Vaccines and Therapy, 2007, 5, 13.	1.5	13
115	Suppression of mouse rhodopsin expression in vivo by AAV mediated siRNA delivery. Vision Research, 2007, 47, 1202-1208.	1.4	61
116	RNA knockdown as a potential therapeutic strategy in Parkinson's disease. Gene Therapy, 2006, 13, 517-524.	4.5	41
117	Mitochondrial Protein Nitration Primes Neurodegeneration in Experimental Autoimmune Encephalomyelitis. Journal of Biological Chemistry, 2006, 281, 31950-31962.	3.4	123
118	801. RNA Gene Therapy Targeting Herpes Simplex Virus. Molecular Therapy, 2006, 13, S310.	8.2	2
119	1032. rAAV Mediated Knock-Down of Tyrosine Hydroxylase in the Substantia Nigra Using a pol II Transcribed siRNA. Molecular Therapy, 2006, 13, S396.	8.2	0
120	709. Adeno-Associated Virus Delivery of siRNAs Leads to a Reduction in Phospholamban Levels. Molecular Therapy, 2006, 13, S274.	8.2	0
121	Down-Regulation of Rhodopsin Gene Expression by AAV-Vectored Short Interfering RNA. , 2006, 572, 233-238.		6
122	Mitochondrial Protein Nitration Primes Neurodegeneration in Experimental Autoimmune Encephalomyelitis. Journal of Biological Chemistry, 2006, 281, 31950-31962.	3.4	33
123	AAVâ€Mediated Gene Transfer Protects Against Mitochondrial Optic Neuropathy in Mice. FASEB Journal, 2006, 20, A920.	0.5	0
124	Gene Therapy for Autosomal Dominant Disorders of Keratin. Journal of Investigative Dermatology Symposium Proceedings, 2005, 10, 47-61.	0.8	34
125	Ribozyme Knockdown of the Î³-Subunit of Rod cGMP Phosphodiesterase Alters the ERG and Retinal Morphology in Wild-Type Mice. , 2005, 46, 3836.		14
126	Intrastriatal rAAV-mediated delivery of anti-huntingtin shRNAs induces partial reversal of disease progression in R6/1 Huntington's disease transgenic mice. Molecular Therapy, 2005, 12, 618-633.	8.2	251

#	Article	IF	Citations
127	Knockdown of wild-type mouse rhodopsin using an AAV vectored ribozyme as part of an RNA replacement approach. Molecular Vision, 2005, 11, 648-56.	1.1	39
128	Design and Validation of Therapeutic Hammerhead Ribozymes for Autosomal Dominant Diseases. , 2004, 252, 221-236.		4
129	SOD2 gene transfer protects against optic neuropathy induced by deficiency of complex I. Annals of Neurology, 2004, 56, 182-191.	5.3	73
130	Hammerhead ribozyme targeting connective tissue growth factor mRNA blocks transforming growth factor-beta mediated cell proliferation. Experimental Eye Research, 2004, 78, 1127-1136.	2.6	24
131	Range of retinal diseases potentially treatable by AAV-vectored gene therapy. Novartis Foundation Symposium, 2004, 255, 179-88; discussion 188-94.	1.1	6
132	Suppression of complex I gene expression induces optic neuropathy. Annals of Neurology, 2003, 53, 198-205.	5.3	83
133	Identification of Candida albicans genes induced during thrush offers insight into pathogenesis. Molecular Microbiology, 2003, 48, 1275-1288.	2.5	63
134	Reduction in Preretinal Neovascularization by Ribozymes That Cleave the A 2B Adenosine Receptor mRNA. Circulation Research, 2003, 93, 500-506.	4.5	32
135	Optic Neuropathy Induced by Reductions in Mitochondrial Superoxide Dismutase. , 2003, 44, 1088.		90
136	Decreased Expression of the Insulin-like Growth Factor 1 Receptor by Ribozyme Cleavage. , 2003, 44, 4105.		14
137	[21] Designing and characterizing hammerhead ribozymes for use in AAV vector-mediated retinal gene therapies. Methods in Enzymology, 2002, 346, 358-377.	1.0	10
138	Rescue of a mitochondrial deficiency causing Leber hereditary optic neuropathy. Annals of Neurology, 2002, 52, 534-542.	5.3	253
139	Inhibition of Gene Expression by Ribozymes William W. Hauswirth, Lynn C. Shaw, Patrick O. Whalen, Jason J. Fritz,. , 2001, 47, 105-124.		1
140	Ribozyme gene therapy: applications for molecular medicine. Trends in Molecular Medicine, 2001, 7, 221-228.	6.7	106
141	Viral-vectored ribozymes as therapy for autosomal dominant retinal disease. Clinical Neuroscience Research, 2001, 1, 118-126.	0.8	0
142	[49] Ribozymes in treatment of inherited retinal disease. Methods in Enzymology, 2000, 316, 761-776.	1.0	12
143	Ribozyme uses in retinal gene therapy. Progress in Retinal and Eye Research, 2000, 19, 689-710.	15.5	37
144	Recombinant Adeno-Associated Virus Vector-Based Gene Transfer for Defects in Oxidative Metabolism. Human Gene Therapy, 2000, 11, 2067-2078.	2.7	33

#	Article	IF	Citations
145	Ribozyme rescue of photoreceptor cells in P23H transgenic rats: Long-term survival and late-stage therapy. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 11488-11493.	7.1	195
146	Ribozyme Gene Therapy for Autosomal Dominant Retinal Disease. Clinical Chemistry and Laboratory Medicine, 2000, 38, 147-53.	2.3	28
147	[48] Production and purification of recombinant adeno-associated virus. Methods in Enzymology, 2000, 316, 743-761.	1.0	152
148	Ribozymes Directed Against Messenger RNAs Associated With Autosomal Dominant Retinitis Pigmentosa. , 1999, , 267-275.		0
149	An RNA Binding Motif in the Cbp2 Protein Required for Protein-stimulated RNA Catalysis. Journal of Biological Chemistry, 1999, 274, 30393-30401.	3.4	6
150	Ribozyme-Mediated Gene Therapy for Autosomal Dominant Retinal Degeneration. , 1999, , 277-291.		0
151	Ribozyme rescue of photoreceptor cells in a transgenic rat model of autosomal dominant retinitis pigmentosa. Nature Medicine, 1998, 4, 967-971.	30.7	396
152	Mitochondrial Structure, Function and Biogenesis. , 1998, , 17-41.		0
153	The Cbp2 Protein Stimulates the Splicing of the Â Intron of Yeast Mitochondria. Nucleic Acids Research, 1997, 25, 1597-1604.	14.5	20
154	Cotranscriptional Splicing of a Group I Intron Is Facilitated by the Cbp2 Protein. Molecular and Cellular Biology, 1995, 15, 6971-6978.	2.3	22
155	Protein-induced Folding of a Group I Intron in Cytochrome b Pre-mRNA. Journal of Biological Chemistry, 1995, 270, 21552-21562.	3.4	22
156	Splicing defective mutants of theCOXIgene of yeast mitochondrial DNA: initial definition of the maturase domain of the group II intron AI2. Nucleic Acids Research, 1994, 22, 2057-2064.	14.5	81
157	Structure-induced Strain Determining the Internal Cyclization Site in the Yeast cobI5 Autocatalytic Intron: Theory and Experimental Tests. Journal of Theoretical Biology, 1993, 164, 121-133.	1.7	6
158	Mutational evidence for competition between the P1 and the P10 helices of a mitochondrial group I intron. Nucleic Acids Research, 1992, 20, 2349-2353.	14.5	11
159	A negative regulating element controlling transcription of the gene encoding acyl-CoA oxidase inSaccharomyces cerevisiae. Nucleic Acids Research, 1992, 20, 3495-3500.	14.5	25
160	The rate and specificity of a group I ribozyme are inversely affected by choice of monovalent salt. Nucleic Acids Research, 1991, 19, 605-609.	14.5	19
161	Protein targeting to peroxisomes. Biochemical Society Transactions, 1990, 18, 85-87.	3.4	7
162	Splicing of COB intron 5 requires pairing between the internal guide sequence and both flanking exons.. Proceedings of the National Academy of Sciences of the United States of America, 1990, 87, 8192-8196.	7.1	23

#	Article	IF	Citations
163	Nuclear and mitochondrial revertants of a mitochondrial mutant with a defect in the ATP synthetase complex. Molecular Genetics and Genomics, 1987, 207, 106-113.	2.4	9
164	Mutants of Saccharomyces cerevisiae deficient in adenine phosphoribosyltransferase. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 1987, 180, 81-87.	1.0	15
165	Hypothesisâ€"A chemical mechanism for the biosynthesis of ATP involving ion-exchange reactions. Archives of Biochemistry and Biophysics, 1984, 232, 496-504.	3.0	9
166	Submitochondrial localization, cell-free synthesis, and mitochondrial import of 2-isopropylmalate synthase of yeast.. Proceedings of the National Academy of Sciences of the United States of America, 1983, 80, 1270-1274.	7.1	31
167	Cytoplasmically made subunits of yeast mitochondrial F1-ATPase and cytochrome c oxidase are synthesized as individual precursors, not as polyproteins.. Proceedings of the National Academy of Sciences of the United States of America, 1980, 77, 3998-4002.	7.1	111
168	Propagation of restriction fragments from the mitochondrial DNA of Saccharomyces cerevisiae in E coli by means of plasmid vectors. Nucleic Acids Research, 1979, 6, 2133-2150.	14.5	25
169	Physical mapping and characterization of the mitochondrial DNA and RNA sequences from mit- mutants defective in cytochrome oxidase peptide 1 (OXI 3). Molecular Genetics and Genomics, 1979, 170, 1-9.	2.4	24
170	Stable heterogeneity of mitochondrial DNA in grande and petite strains of S. cerevisiae. Plasmid, 1979, 2, 474-484.	1.4	15
171	The structure and organization of mitochondrial DNA from petite yeast. Plasmid, 1979, 2, 155-181.	1.4	58
172	Physical mapping of genes on yeast mitochondrial DNA: Localization of antibiotic resistance loci, and rRNA and tRNA genes. Molecular Genetics and Genomics, 1978, 163, 241-255.	2.4	52
173	Restriction enzyme analysis of mitochondrial DNAs of petite mutants of yeast: Classification of petites, and deletion mapping of mitochondrial genes. Molecular Genetics and Genomics, 1978, 163, 257-275.	2.4	72
174	Restriction cleavage map of mitochondrial DNA from the yeast Saccharomyces cerevisiae. Nucleic Acids Research, 1977, 4, 2331-2352.	14.5	38
175	Restriction endonuclease analysis of mitochondrial DNA from grande and genetically characterized cytoplasmic petite clones of Saccharomyces cerevisiae.. Proceedings of the National Academy of Sciences of the United States of America, 1975, 72, 3868-3872.	7.1	38
176	Individual and Synergistic Anti-Coronavirus Activities of SOCS1/3 Antagonist and Interferon Î±1 Peptides. Frontiers in Immunology, 0, 13, .	4.8	6